Related Experiment Video
Updated: Jun 26, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?
1Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. john.senior@fda.hhs.gov
Abstract:
Drug-induced liver injury (DILI) is a major reason drugs fail during development or are withdrawn from the market. The ability to predict, detect, and avoid DILI through appropriate patient selection and effective monitoring has proved to be an elusive goal. Many approved drugs have labeling recommendations for serum enzyme monitoring intended to detect and prevent hepatotoxicity, but such monitoring is often seen as inconvenient, uncomfortable, costly, and inefficient by both patients and doctors, and thus monitoring recommendations are poorly followed, if at all. This review considers whether monitoring works to prevent DILI, whether monitoring recommendations are derived from data or opinions, and whether any better alternatives exist.
Insights
Drug-induced liver injury (DILI) monitoring is often ineffective and poorly followed. This review questions its utility and explores alternative strategies for preventing hepatotoxicity.
Area of Science:
- Pharmacology
- Hepatology
- Drug Development
Background:
- Drug-induced liver injury (DILI) is a significant cause of drug attrition during development and post-market withdrawal.
- Current monitoring strategies for drug-induced hepatotoxicity are often inconvenient and poorly adhered to by patients and clinicians.
- The effectiveness of existing monitoring protocols in preventing DILI is questionable.
Purpose of the Study:
- To critically evaluate the efficacy of current serum enzyme monitoring for preventing DILI.
- To determine if monitoring recommendations are evidence-based or opinion-driven.
- To identify and assess potential alternative strategies for DILI prevention.
Main Methods:
- Literature review and critical analysis of existing studies on DILI.
- Examination of drug labeling recommendations for hepatotoxicity monitoring.
- Comparative assessment of monitoring effectiveness versus alternative approaches.
Main Results:
- Existing monitoring practices for DILI are frequently not followed, limiting their effectiveness.
- Evidence supporting the data-driven basis of many monitoring recommendations is often lacking.
- The inconvenience and inefficiency of current monitoring contribute to poor compliance.
Conclusions:
- Current serum enzyme monitoring strategies for DILI are of questionable value and poorly implemented.
- A re-evaluation of DILI monitoring practices is necessary, prioritizing patient adherence and clinical utility.
- Development and validation of alternative, more effective DILI prevention strategies are warranted.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Hepatic Drug Excretion: Influencing Factors
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Toxicity Testing in Animals

